[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2021245569A3 - Pharmaceutical composition comprising: a bisabolol compound, valencene and a|terpinene compound - Google Patents

Pharmaceutical composition comprising: a bisabolol compound, valencene and a|terpinene compound Download PDF

Info

Publication number
WO2021245569A3
WO2021245569A3 PCT/IB2021/054832 IB2021054832W WO2021245569A3 WO 2021245569 A3 WO2021245569 A3 WO 2021245569A3 IB 2021054832 W IB2021054832 W IB 2021054832W WO 2021245569 A3 WO2021245569 A3 WO 2021245569A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
valencene
terpinene
bisabolol
pharmaceutical composition
Prior art date
Application number
PCT/IB2021/054832
Other languages
French (fr)
Other versions
WO2021245569A2 (en
Inventor
Yusef BABIKYAN
Haig BABIKIAN
Benjamin JIARAVANON
Original Assignee
Rhea Genetics Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhea Genetics Pte. Ltd. filed Critical Rhea Genetics Pte. Ltd.
Priority to GB2218187.9A priority Critical patent/GB2611206A/en
Publication of WO2021245569A2 publication Critical patent/WO2021245569A2/en
Publication of WO2021245569A3 publication Critical patent/WO2021245569A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

There is disclosed a pharmaceutical composition comprising: a bisabolol compound, valencene and a terpinene compound.
PCT/IB2021/054832 2020-06-02 2021-06-02 A composition WO2021245569A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2218187.9A GB2611206A (en) 2020-06-02 2021-06-02 Pharmaceutical composition comprising: a bisabolol compound, valencene and a terpinene compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2008289.7 2020-06-02
GBGB2008289.7A GB202008289D0 (en) 2020-06-02 2020-06-02 A composition

Publications (2)

Publication Number Publication Date
WO2021245569A2 WO2021245569A2 (en) 2021-12-09
WO2021245569A3 true WO2021245569A3 (en) 2022-02-10

Family

ID=71526250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/054832 WO2021245569A2 (en) 2020-06-02 2021-06-02 A composition

Country Status (2)

Country Link
GB (2) GB202008289D0 (en)
WO (1) WO2021245569A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
US20190240191A1 (en) * 2013-09-18 2019-08-08 The Werc Shop, LLC Terpene-Based Compositions, Processes Methodologies
WO2021011413A1 (en) * 2019-07-12 2021-01-21 Atlas Hemp Company Llc. Methods for isolating essential oils, phytochemicals and pharmaceutically active components from biomass and reconstituting synthetic formulations comprising same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240191A1 (en) * 2013-09-18 2019-08-08 The Werc Shop, LLC Terpene-Based Compositions, Processes Methodologies
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
WO2021011413A1 (en) * 2019-07-12 2021-01-21 Atlas Hemp Company Llc. Methods for isolating essential oils, phytochemicals and pharmaceutically active components from biomass and reconstituting synthetic formulations comprising same

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AMBROZ MARTIN ET AL: "The Effects of Selected Sesquiterpenes from Myrica rubra Essential Oil on the Efficacy of Doxorubicin in Sensitive and Resistant Cancer Cell Lines", MOLECULES, vol. 22, no. 6, 20 June 2017 (2017-06-20), pages 1021, XP055871072, DOI: 10.3390/molecules22061021 *
ANTHONY J. DE LUCCA ET AL: "Fungicidal and Bactericidal Properties of Bisabolol and Dragosantol", THE JOURNAL OF ESSENTIAL OIL RESEARCH : JEOR, vol. 23, no. 3, 1 May 2011 (2011-05-01), UK, pages 47 - 54, XP055562418, ISSN: 1041-2905, DOI: 10.1080/10412905.2011.9700457 *
BOUSBIA N ET AL: "A new process for extraction of essential oil from Citrus peels: Microwave hydrodiffusion and gravity", JOURNAL OF FOOD ENGINEERING, BARKING ESSEX, GB, vol. 90, no. 3, 1 February 2009 (2009-02-01), pages 409 - 413, XP025425543, ISSN: 0260-8774, [retrieved on 20080703], DOI: 10.1016/J.JFOODENG.2008.06.034 *
DA SILVA JOYCE KELLY R. ET AL: "Essential Oils as Antiviral Agents, Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation", INT. J. MOL. SCI., vol. 21, no. 10, 12 May 2020 (2020-05-12), pages 3426, XP055787017, ISSN: 1661-6596, DOI: 10.3390/ijms21103426 *
GUIMARÃES ALINE CRISTINA ET AL: "Antibacterial Activity of Terpenes and Terpenoids Present in Essential Oils", MOLECULES, vol. 24, no. 13, 5 July 2019 (2019-07-05), pages 2471, XP055836987, DOI: 10.3390/molecules24132471 *
MAATALLAH S ET AL: "Evaluation changing of essential oil of laurel (Laurus nobilisL.) under water deficit stress conditions", INDUSTRIAL CROPS AND PRODUCTS, ELSEVIER, NL, vol. 91, 19 July 2016 (2016-07-19), pages 170 - 178, XP029681348, ISSN: 0926-6690, DOI: 10.1016/J.INDCROP.2016.07.001 *
PERDONES ÁNGELA ET AL: "Effect of chitosan-lemon essential oil coatings on volatile profile of strawberries during storage", FOOD CHEMISTRY, ELSEVIER LTD, NL, vol. 197, 12 November 2015 (2015-11-12), pages 979 - 986, XP029312209, ISSN: 0308-8146, DOI: 10.1016/J.FOODCHEM.2015.11.054 *

Also Published As

Publication number Publication date
WO2021245569A2 (en) 2021-12-09
GB202008289D0 (en) 2020-07-15
GB202218187D0 (en) 2023-01-18
GB2611206A (en) 2023-03-29

Similar Documents

Publication Publication Date Title
WO2021127404A8 (en) Tricyclic pyridones and pyrimidones
TWD204941S (en) Watch
TWD204816S (en) Ring
AU2020330570A8 (en) Process of making CFTR modulators
WO2019232025A3 (en) Microbial engineering for the production of isoprenoids
EP4375279A3 (en) Cot modulators and methods of use thereof
WO2021257730A3 (en) Cells modified by a cas12i polypeptide
TWD206925S (en) Syringe
TWD203554S (en) Wine cabinet
EP4382129A3 (en) Compounds for fast and efficient click release
WO2018192910A3 (en) Process for making an anti-soiling coating composition and a coating made therefrom
BR112022000725A2 (en) Carboxy-terminated diene rubbers
WO2023009529A3 (en) Novel polypeptides and uses thereof
WO2020235974A3 (en) Single base substitution protein, and composition comprising same
WO2021245569A3 (en) Pharmaceutical composition comprising: a bisabolol compound, valencene and a|terpinene compound
ZA202401345B (en) Polypeptide drug conjugate having novel structure and application thereof
TWD215406S (en) Bottle
TWD231232S (en) Earphone
ZA202303479B (en) Microorganism for producing putrescine and process for producing putrescine by using same
WO2023014908A8 (en) Lpar1 antagonists and uses thereof
MX2024001899A (en) Potassium channel modulators.
TWD227929S (en) Bottle
TWD227753S (en) Bottle
MX2022011082A (en) (s,z)-3,7-dimethylnon-6-en-1-ol and its use as fragrance.
TWD231000S (en) Faucet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21731591

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 202218187

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20210602

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21731591

Country of ref document: EP

Kind code of ref document: A2